福莫司汀预防完全缓解期小细胞肺癌脑转移疗效观察  

Prevention Efficacy of Fotemustine for Brain Metastasis of Small Cell Lung Cancer in Complete Remission

作　　者：黄堃[1] 邝先奎 韩伟[1] 赵向通 闫焱[1] 董文杰[1] 王丽萍[1] 

机构地区：[1]郑州大学第一附属医院肿瘤科,河南郑州450052 [2]项城市第一人民医院肿瘤科,河南周口466200

出　　处：《肿瘤基础与临床》2016年第1期64-67,共4页journal of basic and clinical oncology

基　　金：河南省卫生厅科技攻关项目(编号:201303038)

摘　　要：目的观察福莫司汀对完全缓解期小细胞肺癌脑转移的预防作用。方法 68例完全缓解期小细胞肺癌患者随机分为2组。治疗组31例给予福莫司汀100 mg·m-2,静脉滴注,d1,8,21 d为1周期,重复2周期;对照组37例给予定期复查。比较15个月内2组脑转移发生率、无疾病进展生存期、1 a生存率。结果治疗组脑转移发生率低于对照组,无疾病进展生存期长于对照组,差异有统计学意义(P均<0.05);2组1 a生存率比较差异无统计学意义(P>0.05)。结论早期应用福莫司汀可降低完全缓解期小细胞肺癌脑转移发生风险,延长患者无疾病进展生存期。Objective To assess the prevention efficacy of fotemustine for brain metastasis of small cell lung cancer in complete remission. Methods Sixty-eight patients with small cell lung cancer in complete remission were randomly divided into two groups. The 31 patients in the fotemustine treatment group received fotemustine（ 100 mg·m- 2,ivgtt,d1,8）,21 days was a chemotherapy cycle,2 cycles of chemotherapy were given; the other 37 patients in the control group were given regular review. The 15 month brain metastases rate,progression-free survival and 1-year survival rate were compared between the two groups. Results The 15 month brain metastases rate of the fotemustine treatment group was lower than that of the control group,the progression-free survival was longer than that of the control group（ P 〈0. 05）; there was no statistical difference in the 1-year survival rate between the two groups（ P 〉0. 05）. Conclusion Early application of fotemustine can reduce incidence of brain metastasis of small cell lung cancer in complete remission,and lengthen the progress free survival.

关 键 词：小细胞肺癌 福莫司汀 预防 完全缓解期 脑转移 

分 类 号：R734.2[医药卫生—肿瘤] R730.6[医药卫生—临床医学]